欧洲药品管理局CHMP 11月9至12日会议:推荐批准7款新药,另有11款药获适应症扩展推荐

欧洲药品管理局(EMA)公布其人用药品委员会(CHMP)11月9日至12日会议结果:委员会在本次会议上推荐批准7款新药上市。EMA 总部位于荷兰阿姆斯特丹,CHMP 的意见将送交欧盟委员会作最终决定。
新药方面,委员会推荐授予 Aumseqa(aumolertinib)上市许可,用于治疗非小细胞肺癌;推荐 Baxfendy(baxdrostat)上市,用于治疗控制不足的高血压;Zybrivo(sintilimab)获积极意见,用于成人非鳞状非小细胞肺癌。两款胰岛素生物类似药 Garzulys 与 Donrafylix(均为门冬胰岛素)获积极意见,用于成人、青少年与1岁以上儿童的糖尿病。两款仿制药 Fondaparinux sodium Evumed 与 Ruxolitinib Krka 亦获积极意见。
委员会还推荐11款已上市药扩展适应症,其中包括推荐把 Gazyvaro(obinutuzumab)扩展用于标准治疗控制不佳的中重度活动性系统性红斑狼疮成人患者,并推荐 Isturisa(osilodrostat)扩展至6岁以上儿童与青少年的内源性库欣综合征。
此外,委员会在复审后确认拒绝两款药的上市许可:用于儿童与青少年急性疼痛的 KemSu(舒芬太尼/氯胺酮)与用于尼曼匹克病 C 型的 Meplyffa(arimoclomol)。另有两款药的上市申请被撤回。委员会还通过了一份关于 Mounjaro(替尔泊肽)可能影响口服避孕药可靠性的医务人员直接沟通函,要求育龄女性使用者在起始用药与每次加量后的4周内加用屏障避孕法,或改用非口服避孕方法。
EMA's CHMP Meeting of November 9-12: Seven New Medicines Recommended for Approval, With Indication Extensions Recommended for 11 More
The European Medicines Agency (EMA) has published the highlights of its Committee for Medicinal Products for Human Use (CHMP) meeting of November 9-12, 2026, at which the committee recommended seven new medicines for approval. The EMA is headquartered in Amsterdam, the Netherlands, and CHMP opinions are sent to the European Commission for a final decision.
Among the new medicines, the committee recommended granting a marketing authorisation for Aumseqa (aumolertinib) for non-small cell lung cancer, and for Baxfendy (baxdrostat) for insufficiently controlled hypertension. Zybrivo (sintilimab) received a positive opinion for non-squamous non-small cell lung cancer in adults. Two insulin aspart biosimilars, Garzulys and Donrafylix, received positive opinions for diabetes mellitus in adults, adolescents and children aged 1 year and above, as did two generics, Fondaparinux sodium Evumed and Ruxolitinib Krka.
The committee also recommended extensions of therapeutic indication for 11 medicines, including extending Gazyvaro (obinutuzumab) to adults with moderate-to-severe active systemic lupus erythematosus whose disease is not adequately controlled by standard treatment, and extending Isturisa (osilodrostat) to adolescents and children aged 6 years and older with endogenous Cushing's syndrome.
Following re-examination, the committee confirmed its recommendation to refuse marketing authorisation for two medicines: KemSu (sufentanil/ketamine) for acute pain in children and adolescents, and Meplyffa (arimoclomol citrate) for Niemann-Pick disease type C. Applications for two other medicines were withdrawn. The committee also adopted a direct healthcare professional communication on the potential effect of Mounjaro (tirzepatide) on the reliability of oral contraceptives, advising women who can become pregnant to add a barrier method for four weeks after starting tirzepatide and after each dose increase, or to switch to a non-oral method.
发布:GSM·美国(发布链接)
图片来源:Wikimedia Commons, File:2020 European Medicines Agency.jpg — Author: Ceescamel. Licensing: CC BY-SA 4.0.
GSM Global · 本篇英文版 English edition of this story

